{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:38:52Z","timestamp":1790912332398,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Several blood markers of inflammation are elevated in prostate cancer (PCa) and have prognostic value. Little is known about the relationship between these markers, PCa, and other factors associated with chronic inflammation, such as smoking and obesity. We analyzed the interaction between neutrophil and platelet counts indexed to lymphocyte count (NLR and PLR, resp.) and clinically significant PCa (csPCa), accounting for the potential confounding factors of systemic inflammation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>NLR and PLR were evaluated in a multicenter prospective study in 443 patients. CsPCa was defined as a Gleason\u2009\u2265\u20094\u2009+\u20093. Differences between patients with csPCa and non-csPCA were evaluated using the chi-square test, analysis of variance or the Kruskal-Wallis test. Multivariable logistic regression analysis adjusted for smoking, hypertension, diabetes, and cardiovascular disease, and in separate models, either body mass index or waist-to-hip ratio was used to characterize the relationship between inflammation and csPCa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>None of the factors such as plateletcrit, NLR, and PLR were significantly different between patients with csPCa or non-significant PCa. After adjustment, there was no association between PLR, NLR, plateletcrit or platelet count and csPCa. In an exploratory analysis, there was no association between markers of inflammation and PSA levels\u2009&gt;\u200910 ng\/mL. When testing different NLR cutoffs to predict csPCa in ROC analysis, none reached a clinically meaningful value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In contrast to previous studies, we found no significant association between easily available blood markers of inflammation and indices of PCa aggressiveness. Further research is required to determine whether inflammation promotes PCa. (ClinicalTrials.gov: NCT03127631. Date of registration: April 25, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-024-01617-2","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T03:41:40Z","timestamp":1729050100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio"],"prefix":"10.1186","volume":"24","author":[{"given":"Johanna","family":"Dahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehonathan","family":"Pinthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guila","family":"Delouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Taussky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Duceppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"issue":"5","key":"1617_CR1","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.eururo.2012.11.013","volume":"63","author":"EH Allott","year":"2013","unstructured":"Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800\u20139.","journal-title":"Eur Urol"},{"issue":"1","key":"1617_CR2","doi-asserted-by":"publisher","first-page":"e13088","DOI":"10.1111\/obr.13088","volume":"22","author":"EA Silveira","year":"2021","unstructured":"Silveira EA, Kliemann N, Noll M, Sarrafzadegan N, de Oliveira C. Visceral obesity and incident cancer and cardiovascular disease: an integrative review of the epidemiological evidence. Obes Rev. 2021;22(1):e13088.","journal-title":"Obes Rev"},{"issue":"11","key":"1617_CR3","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.ajpath.2019.07.007","volume":"189","author":"A Rani","year":"2019","unstructured":"Rani A, Dasgupta P, Murphy JJ. Prostate Cancer: the role of inflammation and chemokines. Am J Pathol. 2019;189(11):2119\u201337.","journal-title":"Am J Pathol"},{"issue":"1","key":"1617_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12916-021-02188-x","volume":"19","author":"SC Larsson","year":"2021","unstructured":"Larsson SC, Burgess S. Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of mendelian randomization studies. BMC Med. 2021;19(1):320.","journal-title":"BMC Med"},{"issue":"2","key":"1617_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/jcm8020201","volume":"8","author":"K Fujita","year":"2019","unstructured":"Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, inflammation, and prostate cancer. J Clin Med. 2019;8(2):201.","journal-title":"J Clin Med"},{"issue":"6","key":"1617_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bju.12452","volume":"113","author":"DP Nguyen","year":"2014","unstructured":"Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113(6):986\u201392.","journal-title":"BJU Int"},{"issue":"1","key":"1617_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cncr.31778","volume":"125","author":"MA Bilen","year":"2019","unstructured":"Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019;125(1):127\u201334.","journal-title":"Cancer"},{"issue":"16","key":"1617_CR8","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/pros.24222","volume":"81","author":"MC Cho","year":"2021","unstructured":"Cho MC, Yoo S, Choo MS, Son H, Jeong H. Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy. Prostate. 2021;81(16):1278\u201386.","journal-title":"Prostate"},{"issue":"1","key":"1617_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12894-022-00956-2","volume":"22","author":"DL Jethwani","year":"2022","unstructured":"Jethwani DL, Sivamoorthy LL, Toh CC, Malek R. Predicting the diagnosis of prostate cancer with a scoring system based on novel biomarkers. BMC Urol. 2022;22(1):13.","journal-title":"BMC Urol"},{"key":"1617_CR10","doi-asserted-by":"publisher","first-page":"1228076","DOI":"10.3389\/fonc.2023.1228076","volume":"13","author":"K Heshmat-Ghahdarijani","year":"2023","unstructured":"Heshmat-Ghahdarijani K, Sarmadi V, Heidari A, Falahati Marvasti A, Neshat S, Raeisi S. The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers: a narrative review. Front Oncol. 2023;13:1228076.","journal-title":"Front Oncol"},{"issue":"2","key":"1617_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","volume":"23","author":"Y Guan","year":"2020","unstructured":"Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23(2):220\u201331.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"1617_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI92035","volume":"127","author":"AR Saltiel","year":"2017","unstructured":"Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017;127(1):1\u20134.","journal-title":"J Clin Invest"},{"issue":"4","key":"1617_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/jnci\/djad008","volume":"115","author":"M Sun","year":"2023","unstructured":"Sun M, Fritz J, Haggstrom C, Bjorge T, Nagel G, Manjer J, et al. Metabolically (Un)healthy obesity and risk of obesity-related cancers: a pooled study. J Natl Cancer Inst. 2023;115(4):456\u201367.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"1617_CR14","doi-asserted-by":"publisher","first-page":"nzab106","DOI":"10.1093\/cdn\/nzab106","volume":"5","author":"N Savija","year":"2021","unstructured":"Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, et al. Development and comparability of a short food-frequency questionnaire to assess Diet in prostate Cancer patients: the role of Androgen Deprivation Therapy in CArdiovascular disease - A longitudinal prostate Cancer Study (RADICAL PC) Substudy. Curr Dev Nutr. 2021;5(11):nzab106.","journal-title":"Curr Dev Nutr"},{"issue":"4\u20135","key":"1617_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.euf.2016.10.010","volume":"3","author":"CJ Kane","year":"2017","unstructured":"Kane CJ, Eggener SE, Shindel AW, Andriole GL. Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason score 7, International Society of Urological Pathology Gleason Group 2\u20133) and implications for risk stratification: a systematic review. Eur Urol Focus. 2017;3(4\u20135):487\u201397.","journal-title":"Eur Urol Focus"},{"issue":"9","key":"1617_CR16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1089\/10799900260286623","volume":"22","author":"MH Klinger","year":"2002","unstructured":"Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002;22(9):913\u201322.","journal-title":"J Interferon Cytokine Res"},{"key":"1617_CR17","doi-asserted-by":"crossref","unstructured":"Feiertag N, Tawfik M-M, Loloi J, Patel RD, Green B, Zhu M et al. Should Men Eat More Plants? A Systematic Review of the Literature on the Effect of Plant-Forward Diets on Men\u2019s Health. Urology. 2023.","DOI":"10.1016\/j.urology.2023.03.012"},{"key":"1617_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.semcancer.2023.03.002","volume":"91","author":"G Papavasileiou","year":"2023","unstructured":"Papavasileiou G, Tsilingiris D, Spyrou N, Vallianou NG, Karampela I, Magkos F, et al. Obesity and main urologic cancers: current systematic evidence, novel biological mechanisms, perspectives and challenges. Semin Cancer Biol. 2023;91:70\u201398.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"1617_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/pcan.2009.11","volume":"12","author":"SJ Freedland","year":"2009","unstructured":"Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009;12(3):259\u201363.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1617_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5410\/wjcu.v3.i3.227","volume":"3","author":"JOC-MR Herrera-Caceres","year":"2014","unstructured":"Herrera-Caceres JOC-MR. Functional and metabolic complications of Androgen Deprivation Therapy. World J Clin Urol. 2014;3:227\u201337.","journal-title":"World J Clin Urol"},{"issue":"4","key":"1617_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/bjc.2017.440","volume":"118","author":"MS Farris","year":"2018","unstructured":"Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM. Anthropometric measurements and survival after a prostate cancer diagnosis. Br J Cancer. 2018;118(4):607\u201310.","journal-title":"Br J Cancer"},{"key":"1617_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.thromres.2016.08.012","volume":"148","author":"PJ Vinholt","year":"2016","unstructured":"Vinholt PJ, Hvas AM, Frederiksen H, Bathum L, Jorgensen MK, Nybo M. Platelet count is associated with cardiovascular disease, cancer and mortality: a population-based cohort study. Thromb Res. 2016;148:136\u201342.","journal-title":"Thromb Res"},{"issue":"12","key":"1617_CR23","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1172\/JCI27196","volume":"115","author":"M Gawaz","year":"2005","unstructured":"Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378\u201384.","journal-title":"J Clin Invest"},{"issue":"9","key":"1617_CR24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","volume":"113","author":"G Vilahur","year":"2017","unstructured":"Vilahur G, Ben-Aicha S, Badimon L. New insights into the role of adipose tissue in thrombosis. Cardiovasc Res. 2017;113(9):1046\u201354.","journal-title":"Cardiovasc Res"},{"key":"1617_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.thromres.2021.08.008","volume":"206","author":"JK Rudzinski","year":"2021","unstructured":"Rudzinski JK, Govindasamy NP, Asgari A, Saito MS, Lewis JD, Jurasz P. Preferential interaction of platelets with prostate cancer cells with stem cell markers. Thromb Res. 2021;206:42\u201351.","journal-title":"Thromb Res"},{"issue":"11","key":"1617_CR26","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1111\/jth.15020","volume":"18","author":"JK Rudzinski","year":"2020","unstructured":"Rudzinski JK, Govindasamy NP, Lewis JD, Jurasz P. The role of the androgen receptor in prostate cancer-induced platelet aggregation and platelet-induced invasion. J Thromb Haemost. 2020;18(11):2976\u201386.","journal-title":"J Thromb Haemost"},{"key":"1617_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12885-015-1599-9","volume":"15","author":"H Bahig","year":"2015","unstructured":"Bahig H, Taussky D, Delouya G, Nadiri A, Gagnon-Jacques A, Bodson-Clermont P, et al. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer. 2015;15:594.","journal-title":"BMC Cancer"},{"issue":"5","key":"1617_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s11523-017-0516-3","volume":"12","author":"D Taussky","year":"2017","unstructured":"Taussky D, Soulieres D, Azoulay L, Yin H, Bahig H, Bahary JP, et al. A combination of Testosterone and White Blood Cell Count as a predictive factor of overall survival in localized prostate Cancer. Target Oncol. 2017;12(5):695\u2013701.","journal-title":"Target Oncol"},{"key":"1617_CR29","volume-title":"Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy","year":"2015","unstructured":"Langsenlehner T, Pichler M, Thurner E-M, Krenn-Pilko S, Stojakovic T, Gerger A, et al. editors. Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urologic Oncology: Seminars and Original Investigations; 2015."},{"key":"1617_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12885-016-2363-5","volume":"16","author":"Y Wang","year":"2016","unstructured":"Wang Y, Xu F, Pan J, Zhu Y, Shao X, Sha J, et al. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer. 2016;16:329.","journal-title":"BMC Cancer"},{"key":"1617_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fimmu.2016.00373","volume":"7","author":"AK Olsson","year":"2016","unstructured":"Olsson AK, Cedervall J. NETosis in Cancer - platelet-neutrophil crosstalk promotes Tumor-Associated Pathology. Front Immunol. 2016;7:373.","journal-title":"Front Immunol"},{"issue":"21","key":"1617_CR32","doi-asserted-by":"publisher","first-page":"35255","DOI":"10.18632\/oncotarget.13052","volume":"8","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Fujita K, Tanigawa G, Kawashima A, Nagahara A, Ujike T, et al. Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer. Oncotarget. 2017;8(21):35255.","journal-title":"Oncotarget"},{"issue":"9","key":"1617_CR33","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/1055-9965.EPI-22-0147","volume":"31","author":"CS Langlais","year":"2022","unstructured":"Langlais CS, Graff RE, Van Blarigan EL, Kenfield SA, Neuhaus J, Tabung FK, et al. Postdiagnostic inflammatory, hyperinsulinemic, and insulin-resistant diets and lifestyles and the risk of prostate Cancer progression and mortality. Cancer Epidemiol Biomarkers Prev. 2022;31(9):1760\u20138.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"1617_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/bco2.237","volume":"4","author":"Z Dovey","year":"2023","unstructured":"Dovey Z, Horowitz A, Waingankar N. The influence of lifestyle changes (diet, exercise and stress reduction) on prostate cancer tumour biology and patient outcomes: a systematic review. BJUI Compass. 2023;4(4):385\u2013416.","journal-title":"BJUI Compass"},{"issue":"12","key":"1617_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"1617_CR36","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.eururo.2017.01.044","volume":"72","author":"MK Downer","year":"2017","unstructured":"Downer MK, Allard CB, Preston MA, Gaziano JM, Stampfer MJ, Mucci LA, et al. Regular aspirin use and the risk of Lethal prostate Cancer in the Physicians\u2019 Health Study. Eur Urol. 2017;72(5):821\u20137.","journal-title":"Eur Urol"},{"issue":"5","key":"1617_CR37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ijc.30803","volume":"141","author":"BA Dickerman","year":"2017","unstructured":"Dickerman BA, Ahearn TU, Giovannucci E, Stampfer MJ, Nguyen PL, Mucci LA, et al. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer. 2017;141(5):933\u201344.","journal-title":"Int J Cancer"},{"issue":"16","key":"1617_CR38","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.3390\/cancers13164169","volume":"13","author":"M Rivera-Izquierdo","year":"2021","unstructured":"Rivera-Izquierdo M, P\u00e9rez de Rojas J, Mart\u00ednez-Ruiz V, P\u00e9rez-G\u00f3mez B, S\u00e1nchez M-J, Khan KS, et al. Obesity as a risk factor for prostate cancer mortality: a systematic review and dose-response meta-analysis of 280,199 patients. Cancers. 2021;13(16):4169.","journal-title":"Cancers"},{"issue":"77","key":"1617_CR39","doi-asserted-by":"publisher","first-page":"34485","DOI":"10.18632\/oncotarget.26128","volume":"9","author":"C Lavalette","year":"2018","unstructured":"Lavalette C, Tretarre B, Rebillard X, Lamy PJ, Cenee S, Menegaux F. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget. 2018;9(77):34485\u201394.","journal-title":"Oncotarget"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01617-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T19:03:27Z","timestamp":1729105407000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1617"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01617-2","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This specific study was reviewed and approved by the Hamilton Integrated Research Ethics Board (CTO-0743 Ontario, Canada) before the study began. Written consent was obtained by all participants. All RADICAL-PC participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ED is supported by a clinician-scientist Junior 1 award from the Fonds de Recherche du Qu\u00e9bec Sant\u00e9 and reports research grants for investigator-initiated research from Roche Diagnostics and Abbott Laboratories, both not related to this study. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}